AzTrials
AzTrials

Acute Respiratory InfectionASPIRE IINCT06981130

ASPIRE II. Supporting Antibiotic Stewardship in Primary Care Via POCT

A study testing FebriDx Point of Care Test in people with Acute Respiratory Infection, run by University of South Wales at 3 sites in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Acute Respiratory Infections (ARIs) are a major contributor to antibiotic resistance, largely due to the over prescription of antibiotics driven by the subjective nature of clinical assessment. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Acute Respiratory Infection
What is being tested?
FebriDx Point of Care Test
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
144 participants
Where
3 sitesUnited Kingdom
Study dates
1 Apr 2023to 1 Dec 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Subject >18 years of age.
  • having new onset symptoms suggestive of acute respiratory infection (ARI within 7 days of seeking care: runny nose, nasal congestion, sore throat, cough, hoarse voice, shortness of breath) with or without fever.

Who cannot join

  • Unable to provide informed consent.
  • Undergoing end of life care.
  • Immunocompromised or taking chemotherapy, oral steroids, or interferon.
  • Receiving a live vaccine in the last 14 days.
  • Taking antibiotics or antivirals in the last 14 days.
  • Patients that have symptoms lasting more than 7 days.

Trial locations and contacts

3 sites in 1 country.

United Kingdom3 sites
  • Oaktree Surgery

    Bridgend

  • Kier Hardie Practice 3

    Merthyr Tydfil, Rhondda Cynon Taff

  • Meddygfa Glan Cynon Surgery

    Mountain Ash

Other trials in United Kingdom

About this study

Official title: Supporting Antibiotic Stewardship in Primary Care Via Point-of-care Testing (POCT) for Acute Respiratory Tract Infections: An Interventional Study

Acute Respiratory Infections (ARIs) are a major contributor to antibiotic resistance, largely due to the over prescription of antibiotics driven by the subjective nature of clinical assessment. The ASPIRE II study aims to evaluate whether a Point-of-Care (POC) diagnostic test, utilising C-reactive protein (CRP) and Myxovirus resistance protein A (MxA) biomarkers to differentiate between viral and bacterial infections can support clinical decision-making and serve as an effective antimicrobial stewardship tool.

Read the detailed description

In the first ASPIRE study, in which the POC test was taken after the consultation, 20 participants produced results in the ratio 10:7:3 (negative, bacterial, viral) with a 75% agreement to the antibiotic prescription given by the physician following face-to-face consultation. The observational ASPIRE I Study identified the need for a rapid POC test and highlighted areas in which the test could have been used to prevent over-prescribing of antibiotics when ARI's are identified as viral. The FebriDx POC test was also useful in identifying instances where antibiotics were not prescribed, when a bacterial infection is presented, proving an effective decision-making tool for antibiotic stewardship.

Antibiotic stewardship is fast becoming an essential measure to improve antibiotic prescribing by clinicians. Antibiotic stewardship not only presents a cost-effective strategy for the NHS but addressed the issue of antimicrobial resistance (AMR) and protects patients from harm caused by unnecessary antibiotic use.

The economic costs of antibiotic resistance are largely unknown, but it is anticipated that with an increased number of cases, effects to the economy could be severe. Infections and infectious diseases cost England \& Wales an estimated £30 billion a year, with many cases of acute respiratory infections (Chaplin, 2017). POC diagnostic tests in a clinical setting could give clinicians the ability to distinguish between microbial and viral infections, providing a more informed decision to antibiotic prescribing.

The purpose of this study is to build upon data generated by the ASPIRE study that determined by retrospective evaluation, that a POC immunoassay can accurately be used to guide clinician's prescription decision. The ASPIRE 2 study will use the POC assay as an interventional decision tool prior to the GP's consultation of a suspected acute respiratory infection (ARI).

Upon clinical assessment, the current clinical practice prescribes antibiotics based on symptoms reported by the patient and a subjective review by the GP. This results in antibiotics being prescribed from an informed decision made by the clinician, based only from patient symptoms. The use of a dual marker immunoassay could guide informed decisions based on qualitative data and degree of infection using POC testing in Primary Care.

The POC assay uses a dual marker immunoassay to differentiate between a viral and bacterial infection. C-reactive protein (CRP) is raised in the blood stream in response to inflammation. CRP can be elevated in viral infections, but generally the rise is to higher levels in bacterial infections, especially severe bacterial infections. Another blood protein, the MxA protein, is selectively increased in people with viral infections and therefore has the potential to greatly enhance the rapid distinction between viral and bacterial respiratory infections.

NICE guidance from 2014 recommends the use of CRP POC test in the diagnosis and appropriate management of lower respiratory tract infections in adults aged 18 and over (excluding people with COPD) after clinical assessment whether antibiotics should be prescribed. The study POC assay data could be used as an effective tool alongside NICE guidelines to prescribe antibiotics based on CRP concentration where an infection may be viral. Recent clinical studies suggest the POC test is highly effective, yielding over 80% sensitivity and over 90% specificity when identifying bacterial and viral infections in adults (NICE, 2020).

Being tested
FebriDx Point of Care Test
Keywords
ARI, MxA, CRP, NICE, POC, Primary Care

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • FebriDx Point of Care TestDevice

    Patients self-referring to their GP practice with symptoms of acute respiratory infection (ARI) will receive the FebriDx point-of-care test during their clinical consultation.

Study groups in NCT06981130
Study groupRoleWhat they receive
Patients Suspected with Acute Respiratory InfectionOtherSelf-referred patients presenting ARI symptoms that have met the study inclusion criteria and have been recruited to the study.
Receives: Device: FebriDx Point of Care Test

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Concordance between FebriDx result and clinician decision

    The level of agreement between the FebriDx classification (viral or bacterial) and the clinician's initial diagnostic impression and treatment decision, to prescribe antibiotics or not.

    Measured: End of recruitment period.

Secondary outcomes (1)
  1. Sensitivity and Specificity of FebriDx vs. Clinical Judgement

    Sensitivity (true positive rate) and specificity (true negative rate) of FebriDx in identifying bacterial or viral infections, using clinical decision as reference.

    Measured: End of recruitment period .

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 May 2025
  2. Study start1 Apr 2023
  3. Primary completion1 Jun 2024
  4. Study completion1 Dec 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Not applicable
Intervention model
Single group
Model description
This study follows a single-group assignment model in which all participants presenting to general practice with symptoms of acute respiratory infection (ARI) undergo testing with a Point-of-Care (PoC) diagnostic device. The device measures C-reactive protein (CRP) and Myxovirus resistance protein A (MxA) to help differentiate between viral and bacterial infections. The intervention is applied uniformly, and outcomes such as test performance, diagnostic accuracy, clinician decision-making, and antibiotic prescribing behaviour are monitored prospectively. No randomisation or control arm is included, as the primary objective is to evaluate real-world clinical utility and diagnostic performance in a standard care setting.
Masking
None (open label)
Enrolment
144 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06981130
Sponsor's protocol ID
322984
Acronym
ASPIRE II
Status last verified
May 2025
First submitted
12 May 2025
Last updated
20 May 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing FebriDx Point of Care Test in people with Acute Respiratory Infection, run by University of South Wales at 3 sites in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 20 May 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Concordance between FebriDx result and clinician decision (time frame: End of recruitment period.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 May 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in